XINGANJIANG
873167
Sichuan Goldstone
300434
Hangzhou Huasu Technology
301157
Suzhou Harmontronics Automation Technology
688022
Xinjiang Tianshan Animal Husbandry Bio-engineering
300313
CN Stock MarketDetailed Quotes
688176 Jiangsu Yahong Meditech
- 6.59
- +0.06+0.92%
Market Closed Jan 6 15:00 CST
3.76BMarket Cap-9.32P/E (TTM)
6.64High6.36Low32.11KlotVolume6.57Open6.53Pre Close21.06MTurnover0.86%Turnover RatioLossP/E (Static)570.00MShares10.2252wk High1.81P/B2.45BFloat Cap4.6152wk Low7.84Limit Up371.48MShs Float20.00Historical High5.22Limit Down4.29%Amplitude4.61Historical Low--Dividend TTM6.56Avg Price14.13KlotAsk--Div YieldTTM100Lot Size16.81KlotBid
Jiangsu Yahong Meditech News
Inspection opinions of CITIC Securities Co., Ltd. on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the implementation results of share repurchase
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on shareholders\' voluntary commitment to extend the share lockdown period
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding transactions
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Table_2024 Third Quarter Results Briefing
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 2024 International Papillomavirus Conference
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (November 5, 2024)
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding transactions
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (October 30, 2024)
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on completing the industrial and commercial registration of the change in the company\'s business scope and issuing a business license
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on holding a performance briefing for the third quarter of 2024
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the FDA
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (October 22, 2024)
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on changing the sponsor representative for continuous supervision
